{"id":517365,"date":"2021-07-26T08:03:35","date_gmt":"2021-07-26T12:03:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/"},"modified":"2021-07-26T08:03:35","modified_gmt":"2021-07-26T12:03:35","slug":"twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/","title":{"rendered":"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery"},"content":{"rendered":"

<\/p>\n

Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery<\/b><\/p>\n

SOUTH SAN FRANCISCO, Calif. & KAWASAKI, Japan–(BUSINESS WIRE<\/a>)–
\nTwist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., today announced they generated potent, binding antibodies to an undisclosed oncology target for Twist\u2019s internal pipeline of antibody candidates. The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twist\u2019s antibody discovery and optimization together with MOLCURE\u2019s AI technology.\n<\/p>\n

\n\u201cWe are proud to have engaged in collaborative research with Twist Bioscience, selected by Fast Company as one of the most innovative companies in 2021,\u201d said Ryu Ogawa, Ph.D., CEO of MOLCURE. \u201cOur expectations that this would reinforce our partner\u2019s therapeutic antibody pipelines and further strengthen our AI driven molecule design service were confirmed in this project.\u201d\n<\/p>\n

\n\u201cTwist Bioscience continues to innovate and incorporate the most advanced methods of antibody discovery and optimization into our processes,\u201d said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience. \u201cMOLCURE\u2019s AI approach complements our proprietary antibody discovery and optimization efforts, leveraging technology to refine our internal antibody pipeline. Their platform enables us to find more leads derived from NGS sequencing from our library. We look forward to taking leads generated from this collaboration forward within our internal pipeline.\u201d\n<\/p>\n

About MOLCURE Inc.<\/b><\/p>\n

\nMOLCURE is a growing startup company with a unique biopharmaceutical molecular design technology making full use of Artificial Intelligence (AI). MOLCURE’s patented and validated AI platform is based on evolutionary molecular engineering, next-generation sequencing (NGS), and laboratory automation technologies. MOLCURE is contributing to the development of innovative biopharmaceuticals by creating high-performance drug molecules challenging to develop with traditional technologies.\n<\/p>\n

\nFollow us on Twitter<\/a> | Facebook<\/a> | LinkedIn<\/a><\/p>\n

About Twist Bioscience Corporation<\/b><\/p>\n

\nTwist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by \u201cwriting\u201d DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.\n<\/p>\n

\nFollow us on Twitter<\/a> | Facebook<\/a> | LinkedIn<\/a> | YouTube<\/a><\/p>\n

Legal Notice Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability of the collaborative research project to refine Twist\u2019s internal antibody pipeline, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience\u2019s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience\u2019s patents or proprietary rights; and the risk that Twist Bioscience\u2019s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience\u2019s business in general, see Twist Bioscience\u2019s risk factors set forth in Twist Bioscience\u2019s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on May 7, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210726005249\/en\/<\/a><\/span><\/p>\n

\nAngela Bitting
\n
SVP, Corporate Affairs
\n
925-202-6211
\n
abitting@twistbioscience.com
\n<\/a><\/p>\n

Thomas Jonsson
\n
Business Development Director
\n
+819065067580
\n
thomas@molcure.io<\/a><\/p>\n

KEYWORDS:<\/b> United States Japan North America Asia Pacific California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Technology Research Genetics Software Biotechnology Health Pharmaceutical Science Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery SOUTH SAN FRANCISCO, Calif. & KAWASAKI, Japan–(BUSINESS WIRE)– Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., today announced they generated potent, binding antibodies to an undisclosed oncology target for Twist\u2019s internal pipeline of antibody candidates. The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twist\u2019s antibody discovery and optimization together with MOLCURE\u2019s AI technology. \u201cWe are proud to have engaged in collaborative research with Twist Bioscience, selected by Fast Company as one of the most innovative companies in 2021,\u201d said Ryu Ogawa, Ph.D., … <\/p>\n

Continue reading “Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-517365","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTwist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery SOUTH SAN FRANCISCO, Calif. & KAWASAKI, Japan–(BUSINESS WIRE)– Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., today announced they generated potent, binding antibodies to an undisclosed oncology target for Twist\u2019s internal pipeline of antibody candidates. The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twist\u2019s antibody discovery and optimization together with MOLCURE\u2019s AI technology. \u201cWe are proud to have engaged in collaborative research with Twist Bioscience, selected by Fast Company as one of the most innovative companies in 2021,\u201d said Ryu Ogawa, Ph.D., … Continue reading "Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-26T12:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery\",\"datePublished\":\"2021-07-26T12:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/\"},\"wordCount\":800,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/\",\"name\":\"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-07-26T12:03:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/","og_locale":"en_US","og_type":"article","og_title":"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery - Market Newsdesk","og_description":"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery SOUTH SAN FRANCISCO, Calif. & KAWASAKI, Japan–(BUSINESS WIRE)– Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., today announced they generated potent, binding antibodies to an undisclosed oncology target for Twist\u2019s internal pipeline of antibody candidates. The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twist\u2019s antibody discovery and optimization together with MOLCURE\u2019s AI technology. \u201cWe are proud to have engaged in collaborative research with Twist Bioscience, selected by Fast Company as one of the most innovative companies in 2021,\u201d said Ryu Ogawa, Ph.D., … Continue reading \"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-26T12:03:35+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery","datePublished":"2021-07-26T12:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/"},"wordCount":800,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/","name":"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-07-26T12:03:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210726005249r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-incorporates-molcure-ai-technology-to-augment-therapeutic-antibody-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/517365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=517365"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/517365\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=517365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=517365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=517365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}